Employees: 1,477
Size OrbusNeich Medical (6929.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $394M, the 816th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.83 on 18 Nov 2026.
Performance Over six months the shares fell 15.0%, against -22.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 16.2% over the last twelve months (peer median +13.9%); the operating margin is 23.0% (peer median 4.2%).
Valuation It trades at 8.4× forward earnings against a peer median of 18.2× (2nd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -33 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.8 points above its cost of capital (6.6% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.53B | HK$1.41B | HK$1.28B | HK$1.20B | HK$1.07B |
| Revenue growth | — | +10% | +6% | +12% | — |
| Gross profit | HK$1.05B | HK$936M | HK$875M | HK$821M | HK$711M |
| EBITDA | HK$407M | HK$350M | HK$310M | HK$324M | HK$258M |
| Net income | HK$341M | HK$327M | HK$310M | HK$353M | HK$145M |
| Free cash flow | HK$193M | HK$106M | HK$122M | HK$168M | HK$165M |
| Capital expenditure | HK$199M | HK$143M | HK$87.9M | HK$58.6M | HK$26.1M |
| Total debt | n/a | HK$30.5M | HK$32.6M | HK$58.3M | HK$31.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6929.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.7% | -11.5% | 4th highest of 21 |
| 6-month return | -15.0% | -22.4% | 8th highest of 20 |
| Distance from 52-week high | -21.5% | -45.3% | 3rd highest of 21 |
| Revenue growth (TTM) | +16.2% | +13.9% | 9th highest of 21 |
| Operating margin | 23.0% | 4.2% | 4th highest of 21 |
| Forward P/E | 8.4× | 18.2× | 2nd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -17.6% | -0.1% | least demanding of 12 |
| Growth delivered (Del g) | +15.4% | +15.9% | 5th lowest of 12 |
| Hurdle (Req g minus delivered) | -33.1 pp | -1.0 pp | 3rd least demanding of 12 |
| ROIC minus cost of capital | +9.8 pp | -2.1 pp | 8th highest of 20 |
| EV / EBITDA | 3.9× | 11.6× | cheapest of 9 |
| Net debt / EBITDA | -3.7× | -1.2× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 8.4× | -17.6% | +15.4% |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | n/a | 41.7% | +15.9% |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 15.2× | -6.3% | +247.0% |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | n/a | n/a | n/a |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | n/a | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | n/a | n/a | n/a |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | n/a | -9.5% | -6.6% |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 8.4× | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 19.8× | 9.6% | +5.6% |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 11.3× | -10.3% | +16.9% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 37.2× | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | n/a | 17.1% | +18.1% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | n/a | n/a | n/a |
| Jenscare Scientific 9877.HK | Hong Kong | $415M | -32% | +993% | -106% | n/a | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 25.3× | -4.2% | -6.0% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 20.3× | 24.9% | +18.8% |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $418M | -22% | +46% | 8% | n/a | n/a | n/a |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $425M | -16% | +10% | 27% | 13.2× | -0.1% | +15.6% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |